Higher FGF23 serum levels correlate with reduced survival in patients with tumors and bone metastases,[43] and there is upregulation of FGF23 mRNA in BC.[44] While current research predominantly investigates the correlation between FGF23 and BC, it does not delve into causality. This evidence concerns the gene FGF23 and breast cancer.